



**The Older the Better:  
Are Elderly Study Participants More Nonrepresentative?**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-000833
Article Type:	Research
Date Submitted by the Author:	27-Jul-2012
Complete List of Authors:	Golomb, Beatrice; University of California San Diego, Medicine Chan, Virginia; University of California, San Diego, Department of Medicine Evans, Marcella; University of California, San Diego, Department of Medicine Koperski, Sabrina; University of California, San Diego, Department of Medicine White, Halbert; University of California, San Diego, Department of Economics
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Evidence based practice, Geriatric medicine
Keywords:	EDUCATION & TRAINING (see Medical Education & Training), GENERAL MEDICINE (see Internal Medicine), GERIATRIC MEDICINE, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts

Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

CONFIDENTIAL: DO NOT SHARE

CONFIDENTIAL: DO NOT SHARE

**The Older the Better:**

**Are Elderly Study Participants More Nonrepresentative?**

Beatrice A. Golomb, MD, PhD \* †

Virginia T. Chan, BS, BA \* ‡

Marcella A. Evans, BS \* ‡

Sabrina Koperski, BS \*

Halbert L. White, PhD ¶

Michael H. Criqui, MD, MPH \* †

\* Department of Medicine, University of California, San Diego

† Department of Family and Preventive Medicine, University of California, San Diego

‡ University of California, Irvine School of Medicine

¶ Department of Economics, University of California, San Diego

Running Title: Golomb 2012 - Elderly Nonrepresentative

Corresponding Author & Reprint Requests:

Beatrice A. Golomb, MD, PhD

UCSD Department of Medicine

9500 Gilman Drive # 0995

La Jolla, CA 92093-0995 U.S.A

Phone: 858-558-4950 ext. 201

Fax: 858-558-4960

Email: [bgolomb@ucsd.edu](mailto:bgolomb@ucsd.edu)

Word Count: 1,718

**Abstract 247**

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 Objective: Study subjects can differ from the target population they are taken to represent. We  
4  
5 sought to investigate whether age modifies such differences.  
6  
7

8 Design: Cross-sectional examination of the relation of age to reported “relative activity”  
9  
10 (compared to others of the same age), a bidirectionally-correlated proxy for relative vitality, in  
11  
12 exemplars of randomized and observational studies.  
13  
14

15 Setting: University of California, San Diego (UCSD)  
16

17 Participants: 2,404 adults age 40-79 including employees of UCSD, and their partners (San  
18  
19 Diego Population Study, observational study). 1,016 adults not on lipid medications and without  
20  
21 known heart disease, diabetes, cancer or HIV (UCSD Statin Study, randomized trial).  
22  
23

24 Measurements: Self-rated activity relative to others one’s age, 5-point Likert Scale, was  
25  
26 evaluated by age decade; and related via correlation and regression to a suite of health-relevant  
27  
28 subjective and objective outcomes.  
29  
30

31 Results: Successively older participants reported successively greater activity relative to others  
32  
33 their age (greater departure from the norm for their age),  $p < 0.001$  in both studies. Relative  
34  
35 activity significantly predicted (in regression adjusted for age) actual activity (times/week  
36  
37 exercised); and numerous self-rated and objective health-predictors. These included general self-  
38  
39 rated health, CES-D (depression score), sleep, tiredness, energy; body mass index, waist  
40  
41 circumference, serum glucose, HDL-cholesterol, triglycerides, and white blood cell count.  
42  
43  
44 Indeed some health-predictor associations with age in participants were “paradoxical,” consistent  
45  
46 with greater apparent health in older age – for study participants.  
47  
48  
49

50 Conclusion: Study participants may not be representative of the population they are intended to  
51  
52 reflect. Our results suggest that departures from representativeness may be amplified with  
53  
54 increasing subject age.  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 Trial Registration: UCSD Statin Study – Clinicaltrials.gov # NCT00330980

4  
5  
6 (<http://ClinicalTrials.gov>)

7  
8 **Keywords:** elderly; representativeness; sample selection; generalizability

9  
10 **Abbreviations:** UCSD – University of California, San Diego

11  
12 **What this paper adds:**

13  
14  
15 Section 1 – What is already known about the subject?

16  
17  
18 Study participants differ from the general population they are taken to represent and may be  
19  
20 healthier.

21  
22 Section 2 – What this study adds

23  
24  
25 This study demonstrated that with increasing age, self-selected study participants diverge  
26  
27 increasingly from the population they are taken to represent. This has implications for studies of,  
28  
29 and including, elderly subjects; affecting generalizability to older real-world populations.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Relevance of data from human research studies to the general population depends on the similarity of study participants to those they are taken to represent, i.e. the “target” population. It is recognized that study samples may differ from the target population<sup>1,2</sup>. Often the study sample directly or disproportionately excludes the elderly<sup>3-5</sup> who have worse health and higher expected mortality<sup>6</sup>, and who may differ from younger subjects in treatment effects.

Although there has been increasing emphasis (at least in principle) on inclusion of the elderly in studies<sup>7</sup>, there are reasons for concern that elderly study participants may be less representative of their age group than younger subjects.

Self-selection by subjects themselves of a relatively healthier and more functional study population may occur in all ages<sup>8-11</sup>, since even morbidity not requiring exclusion may nonetheless inhibit participation<sup>1</sup>. But since health problems and functional limitations that lead to self-exclusion may increasingly affect those older in age, we theorized that older age participants might be progressively less representative in indices relevant to function and vitality. Direct comparison of consenting participants to nonparticipants is problematic, since inherently the researcher has access only to the former group. Subjects’ ratings of themselves relative to others their age provides a tentative approach to evaluate whether departures rise with age, if such relative measures can be validated against direct measures.

We validated relative-activity, compared to other individuals ones age, against an activity metric that is absolute (vs relative); and assessed its relation to health-relevant outcomes. We examined reported relative-activity, compared to other individuals ones age, from available exemplars of two types of medical studies (observational and randomized controlled trial) to

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 evaluate whether reported departure from normative function rises with increasing participant  
4  
5 age.  
6  
7  
8  
9

**Methods**Randomized Controlled Trial Subjects:

10  
11  
12  
13  
14  
15 1,016 male and female subjects age 20-85 from the San Diego area were enrolled in the  
16  
17 UCSD Statin Study, a double-blind, randomized, placebo-controlled trial assessing effects of  
18  
19 statin cholesterol-lowering drugs on a relatively broadly sampled group of adults (a primary  
20  
21 prevention sample). There was no imposed upper age limit. Subjects were men over age 20 and  
22  
23 nonprocreative women not on lipid medications and without extremes of LDL-cholesterol (high  
24  
25 or low), diagnosed cardiovascular disease, diabetes or HIV. More information on study  
26  
27 population and design is available elsewhere<sup>12</sup>.  
28  
29  
30  
31  
32  
33

Observational Study Subjects:

34  
35  
36 2,404 selected men and women ages 40-79 were enrolled in the San Diego Population  
37  
38 Study, a population-based observational study identifying prevalence of arterial and venous  
39  
40 disease. Subjects were drawn from current and former employees of the University of California  
41  
42 San Diego (UCSD), as well as their spouses/ significant others – inclusion of which modestly  
43  
44 extended the age range of participants in both directions<sup>13</sup>. In addition, a small number of non-  
45  
46 UCSD volunteers were included. Subjects represented a spectrum of socioeconomic status,  
47  
48 including unemployed and retired as well as working persons. A full description of the study  
49  
50 population is available elsewhere<sup>13</sup>.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

Both studies were approved by the UCSD Human Research Protections Program, and all subjects gave informed consent to participate.

Relative Activity variable:

In both studies, “activity relative to others your age” was queried at baseline and measured on a 5-point Likert scale (1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active). Single-item self-rated assessments have shown strong predictive validity<sup>14-16</sup>.

Validation Variables:

*Other measures used:* From the randomized trial, several other variables were chosen against which to validate the relative activity variable.

*Absolute activity:* We validated the relation of this relative activity measure to self-reported actual exercise frequency (number of episodes of vigorous exercise for at least 20 minutes over a week).

*Health Predictor Variables:* Self-rated and questionnaire variables known to predict mortality and health outcomes that were considered against relative activity included depressed mood (Center for Epidemiological Studies – Depression Scale aka CES-D, and self-rated), and single-item self-ratings of energy, tiredness, muscle weakness, fatigue with exertion, overall health, and satisfaction with health. Objective measures included platelet count (acute phase reactant), white blood count, serum glucose, HDL-cholesterol, triglycerides, body mass index (BMI), and waist circumference.

### Analyses:

Activity associations and health implications of the relative activity measure were examined in older study participants (age > 50) from the randomized trial sample (in which these health variables were assessed), using correlation; and also regression analysis. In the latter, age-relative activity was the independent variable, and assessments were adjusted for actual age. For both study samples, we conducted bivariate analyses examining reported relative activity level as a function of age decade. This was followed by multivariable regression using ordinal logit with robust standard errors (aka White standard errors)<sup>17</sup> controlling for sex, ethnicity (categorical variable) and education (scaled from 1=grade school or less to 9=doctoral degree). All analyses were conducted using Stata™ version 8.0; StataCorp, College Station, Texas. Two-sided P-values less than 0.05 were designated statistically significant.

### **Results**

Self-reported activity relative to others ones age related strongly to actual activity: (unadjusted) correlation 0.42,  $p < 0.0001$ ; (adjusted) regression beta (SE) 1.2 (0.092),  $p < 0.001$ .

Self-rated activity relative to others ones age also related strongly to multiple measures known to predict health, healthcare utilization and mortality, such as general self-rated health, energy, tiredness, depression (CES-D), sleep, muscular weakness, fatigue with exertion, and metabolic syndrome factors of HDL, triglycerides, BMI, waist circumference and serum glucose (Table 1).



## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Self-rated relative physical activity showed a graded positive relation to age on unadjusted analysis ( $p < 0.001$ ) (**Table 2**). This was true in each the clinical trial sample and the observational study sample. Findings were monotonic in the observational sample, and nearly so in the clinical trial sample for subjects from their 40s to 80s.

Multivariable regression (**Table 3**) affirmed that a significant relation of age to reported relative activity was retained with adjustment for variables (sex, ethnicity and education level) that could relate to both age and activity of participants ( $p < 0.001$ ).

## Discussion

To our knowledge this is the first explicit demonstration that progressively older study subjects may depart successively more from parity with those they are taken to represent. This was found in exemplars of both observational studies and clinical trials. Adults in their 30s and 40s reported being only modestly more active than others their age (closest to “about as active” as others). By the oldest decades, participants had surpassed the “somewhat more active” mark, even on average, and were partway, on average, toward the maximum rating of “much more active” compared to others their age. These differences by age were strongly significant.

This finding is concordant with expectations that might be generated from previous observations linking study participation with higher health and vitality. All subjects who self-select for study participation may differ in systematic ways from the target population or population as a whole<sup>8-11</sup>. Prior studies have noted that clinical trial participants are generally younger and healthier than referred and registry patients<sup>4</sup>. Our results further show that successively older subjects *who do* participate in research studies may be successively less

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 typical of their age cohort in a metric with an expected – and indirectly observed – relation to  
4 health. For instance, it related to general self-rated health, which has been found to strongly  
5 predict physical function/disability, health care utilization, and mortality<sup>14-16</sup>. Relative activity  
6 also related in expected directions to other assessed factors known to predict health and mortality  
7 in elderly, such as fasting glucose<sup>18</sup>, white blood cell count<sup>19</sup>, HDL-cholesterol<sup>20</sup>, sleep  
8 problems<sup>21 22</sup>, and depression<sup>23-29</sup>.  
9

10  
11 Selective participation by healthier elderly has potential to influence trial outcomes. This  
12 is particularly true for outcomes for which vitality, function, activity, or any of the range of  
13 health-relevant correlates of relative activity, may serve as effect modifiers. (Such health  
14 correlates include those elucidated here, and presumably many others that were not examined.)  
15  
16 The study also has relevance for outcomes for which differences in subjects' activity and/or  
17 function, through their relation to expected health, may modify study power. For example, a  
18 doubling or halving of mortality by an intervention (or with a risk factor), even in the absence of  
19 effect modification, will have lower statistical power in a sample with lower baseline risk of  
20 mortality outcomes (as a healthier sample portends). Healthier elderly may reduce power for the  
21 risk-side of the equation, which can shift the apparent risk-benefit balance.  
22  
23

24  
25 Limitations of the present analysis are several. Activity relative to others of the same age  
26 was assessed by self-report. Objective evaluation of nonparticipants, to permit direct comparison,  
27 is inherently problematic (as they have not consented to participate). This limitation is mitigated  
28 by demonstration of strongly significant relationships of relative activity to health predictors  
29 within the study population. (A relation to hard outcomes could not be assessed: the  
30 observational study was not longitudinal, and the trial sample enrolled generally healthy  
31 participants with only six-months follow-up.)  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

It is possible that subjects may over-represent their functional state relative to others; but this would not produce an expected age association. In principle, older subjects may differ from younger subjects in the manner of such amplification, but there is little reason to believe this is the case, and the age-adjusted association of our relative activity measure to an exercise frequency measure further diminishes this concern. There is reason to predict that as limiting comorbidities and disabilities accrue with rising age, and as function and the ability to sustain activity declines progressively with age, more elderly individuals will more often find participation too burdensome – yielding a successively more rarefied sample that is progressively more nonrepresentatively robust and healthy, compatible with the findings shown. Indeed, better health has been reported to influence self-selection for participation in studies in general<sup>1</sup>, an observation that might be predicted to drive the finding observed, since health problems increase in prevalence with increasing age.

Factors driving self-selection for participation may vary depending on the character of the study. Although theoretical considerations suggest our findings may generalize broadly, other studies should evaluate how these findings are moderated based on the type of study and condition being examined.

In conclusion, as subject age advances, those who participate in clinical trials and observational studies may depart increasingly from those they are taken to represent, in physical activity and, likely, in health. This potential lack of representativeness should be borne in mind when interpreting studies that include, or focus upon, older subjects. Our finding has fundamental implications for how results in elderly study participants may reflect on elderly more generally, implications which rise in importance as the population continues to age.

## Acknowledgements

The UCSD Statin Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, RO1 HL63055 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. The San Diego Population Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, grant RO1 53487 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. We gratefully thank the staff and subjects from both the UCSD Statin Study and the San Diego Population Study; and the staff from the UCSD GCRC.

## Disclaimers

Competing Interest Statement: *All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare that all authors have no relationships with any companies that might have an interest in the submitted work in the previous 3 years; nor do their spouses, partners, or children have any financial relationships that may be relevant to the submitted work; and none of the authors have any non-financial interests that may be relevant to the submitted work.*

Financial Support: NHLBI RO1 HL63055; NHLBI RO1 HL53487 and, NIH General Clinical Research Center Program grant MO1 RR0827. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of this report.

Author Contributions: All authors, external and internal, had full access to all of the data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis.

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 The authors certify that this manuscript represents valid work and has not been published or is  
4 currently under consideration for publication elsewhere.  
5  
6

7  
8 Data Sharing: Technical appendix, statistical code, and dataset available from the corresponding  
9 author ([bgolomb@ucsd.edu](mailto:bgolomb@ucsd.edu)).  
10  
11

12 Exclusive Licence: The Corresponding Author has the right to grant on behalf of all authors and  
13 does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
14 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit  
15 this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and  
16 sublicences to exploit all subsidiary rights, as set out in our licence  
17 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References**

1. Ganguli M, Lytle ME, Reynolds MD, Dodge HH. Random versus volunteer selection for a community-based study. *J Gerontol A Biol Sci Med Sci* 1998;53(1):M39-46.
2. Kennedy WA, Laurier C, Malo JL, Ghezze H, L'Archeveque J, Contandriopoulos AP. Does clinical trial subject selection restrict the ability to generalize use and cost of health services to "real life" subjects? *Int J Technol Assess Health Care* 2003;19(1):8-16.
3. Swenson WM. Sample selection bias in clinical research. *Psychosomatics* 1980;21(4):291-2.
4. Kaiser C, Jeger R, Wyrsh S, Schoeb L, Kuster GM, Buser P, et al. Selection bias of elderly patients with chronic angina referred for catheterization. *Int J Cardiol* 2006;110(1):80-5.
5. Turazza FM, Franzosi MG. Is anticoagulation therapy underused in elderly patients with atrial fibrillation? *Drugs Aging* 1997;10(3):174-84.
6. Fernandez-Merino MC, Rey-Garcia J, Tato A, Beceiro F, Barros-Dios J, Gude F. [Self-perception of health and mortality in elderly from a rural community]. *Aten Primaria* 2000;25(7):459-63.
7. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. *Intern Med J* 2006;36(4):216-20.
8. Bornehag CG, Sundell J, Sigsgaard T, Janson S. Potential self-selection bias in a nested case-control study on indoor environmental factors and their association with asthma and allergic symptoms among pre-school children. *Scand J Public Health* 2006;34(5):534-43.
9. Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, et al. Selection bias in clinical trials. *J Clin Oncol* 1985;3(8):1142-7.
10. Sugisawa H, Kishino H, Sugihara Y, Okabayashi H, Shibata H. [Comparison of characteristics between respondents and nonrespondents in a national survey of Japanese elderly using six year follow-up study]. *Nippon Kosshu Eisei Zasshi* 1999;46(7):551-62.
11. Sugisawa H, Kishino H, Sugihara Y, Shibata H. [Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly]. *Nippon Kosshu Eisei Zasshi* 2000;47(4):337-49.
12. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. *Control Clin Trials* 2004;25(2):178-202.
13. Criqui MH, Jamosmos M, Fronck A, Denenberg JO, Langer RD, Bergan J, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. *Am J Epidemiol* 2003;158(5):448-56.
14. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. *J Gen Intern Med* 2006;21(3):267-75.
15. DeSalvo KB, Fan VS, McDonnell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. *Health Serv Res* 2005;40(4):1234-46.
16. DeSalvo KB, Fisher WP, Tran K, Bloser N, Merrill W, Peabody J. Assessing measurement properties of two single-item general health measures. *Qual Life Res* 2006;15(2):191-201.
17. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. *Econometrica* 1980;48:817-38.
18. Simons LA, Friedlander Y, McCallum J, Simons J. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. *Aust N Z J Med* 2000;30(1):41-7.

## Golomb 2012 – Elderly Nonrepresentative

19. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. *J Clin Epidemiol* 2001;54(3):316-22.
20. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons [see comments]. *Jama* 1995;274(7):539-44.
21. Lan TY, Lan TH, Wen CP, Lin YH, Chuang YL. Nighttime sleep, Chinese afternoon nap, and mortality in the elderly. *Sleep* 2007;30(9):1105-10.
22. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. *J Intern Med* 2002;251(3):207-16.
23. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gauden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Archives of Internal Medicine* 2001;161(15):1849-56.
24. Blazer DG, Hybels CF, Pieper CF. The association of depression and mortality in elderly persons: a case for multiple, independent pathways. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2001;56(8):M505-9.
25. Schoevers RA, Geerlings MI, Deeg DJ, Holwerda TJ, Jonker C, Beekman AT. Depression and excess mortality: evidence for a dose response relation in community living elderly. *Int J Geriatr Psychiatry* 2009;24(2):169-76.
26. Kawamura T, Shioiri T, Takahashi K, Ozdemir V, Someya T. Survival rate and causes of mortality in the elderly with depression: a 15-year prospective study of a Japanese community sample, the Matsunoyama-Niigata suicide prevention project. *J Investig Med* 2007;55(3):106-14.
27. Peters R, Pinto E, Beckett N, Swift C, Potter J, McCormack T, et al. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing* 2010;39(4):439-45.
28. Janzing JG, Bouwens JM, Teunisse RJ, Van't Hof MA, Zitman FG. The relationship between depression and mortality in elderly subjects with less severe dementia. *Psychological Medicine* 1999;29(4):979-83.
29. Kuo PL, Pu C. The contribution of depression to mortality among elderly with self-reported hypertension: analysis using a national representative longitudinal survey. *J Hypertens* 2011;29(11):2084-90.

Table 1. Activity Ratings by Age

	Clinical Trial Sample		Observational Sample	
Age Decade	N	Relative Activity* Mean (SD)	N	Relative Activity* Mean (SD)
30s	80	3.35 (1.02)	34	3.26 (1.24)
40s	180	3.30 (1.20)	565	3.27 (1.23)
50s	308	3.49 (1.20)	650	3.68 (1.15)
60s	261	3.92 (1.07)	569	3.94 (1.05)
70s	151	3.89 (1.01)	512	3.97 (1.04)
80s	20	4.10 (1.07)	24	4.17 (1.31)
Significance of Change by Age Decade		P < 0.001		P < 0.001

N – Number; SD – Standard deviation

\* Level of physical activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.



Golomb 2012 – Elderly Nonrepresentative

**Table 2. Older Participant Age Associated with Greater Self-reported Relative Activity Level, Ordinal Logit Analyses**

	Clinical Trial Sample				Observational Sample			
	Coefficient for Age Decade	Standard Error	p-value	95% Confidence Interval	Coefficient for Age Decade	Standard Error	p-value	95% Confidence Interval
<b>Unadjusted</b>	0.29	0.044	<0.001	0.21, 0.38	0.37	0.034	<0.001	0.31, 0.44
<b>Multivariable adjusted*</b>	0.35	0.052	<0.001	0.25, 0.45	0.37	0.035	<0.001	0.30, 0.44

- Ordinal logit, Activity level as outcome, adjusted for age, gender, ethnicity, and education level.

Table 3: Self-Rated Relative Activity: Predicts Health-Predictors in Age &gt; 50

Variable	Correlation Coefficient	P-value	Regression Coefficient age adjusted*	P-value	Age Relation
Times/wk exercise at least 20minutes	0.42	<0.0001	1.2 (0.092)	<0.001	(-) 0.024
CES-D (0-52)	-0.21	<0.0001	-1.3 (0.23)	<0.001	NS
Depressed (0-10)	-0.13	0.0083	-0.21 (0.086)	0.017	NS
Energy (0-10)	0.21	<0.0001	0.34 (0.064)	<0.001	(+) 0.031
Sleep problems (0-10)	-0.084	0.028	-0.21 (.095)	0.024	NS
Sleep quality (0-30)	0.078	0.036	0.037 (0.011)	0.001	(+) 0.081
Tired (0-10)	-0.29	<0.0001	-0.72 (0.13)	<0.001	(+) 0.001
Muscle weakness	-0.14	<0.0001	-0.29 (0.070)	<0.001	(+) 0.005
Fatigue w Exertion (0-10)	-0.26	<0.0001	-0.61 (0.12)	<0.001	(+) 0.002
Health (0-10)	0.20	<0.0001	0.31 (0.061)	<0.001	(+) 0.071
Satisfaction with health (0-100)	0.30	<0.0001	5.6 (0.69)	<0.001	NS
Glucose (mg/dL)*	-0.073	0.049	-0.73 (0.31)	0.019	(+) 0.014
HDL (mg/dL)	0.10	0.0063	1.2 (0.53)	0.028	(+) 0.001
Triglycerides (mg/dL)	-0.17	<0.0001	-10 (2.3)	<0.001	NS
Body mass index	-0.26	<0.0001	-0.97 (0.15)	<0.001	(-) 0.002
Waist (cm)	-0.23	<0.0001	-3.9 (0.63)	<0.001	NS
Platelets	-0.073	0.051	-2.7 (1.7)	0.11	(-) 0.043
White blood cell count	-0.08	0.027	-0.125 (0.050)	+0.012	(+) 0.058

\*Relative Activity level for age as the predictor, with age as an adjusted covariate in the regressions, in age > 50

†Note: patients with diabetes or measured glucose over 142 were excluded. This finding is thus despite range restriction.

Note that in these study *participants*, there is a “paradoxically” favorable age association for some variables that generally worsen with rising age, including energy, sleep quality, health, and HDL-cholesterol.



**The Older the Better:  
Are Elderly Study Participants More Nonrepresentative?**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-000833.R1
Article Type:	Research
Date Submitted by the Author:	16-Oct-2012
Complete List of Authors:	Golomb, Beatrice; University of California San Diego, Medicine Chan, Virginia; University of California, San Diego, Department of Medicine Evans, Marcella; University of California, San Diego, Department of Medicine Koperski, Sabrina; University of California, San Diego, Department of Medicine White, Halbert; University of California, San Diego, Department of Economics Criqui, Michael; University of California, San Diego, Department of Medicine; University of California, San Diego, Department of Family and Preventive Medicine
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Evidence based practice, Geriatric medicine
Keywords:	EDUCATION & TRAINING (see Medical Education & Training), GENERAL MEDICINE (see Internal Medicine), GERIATRIC MEDICINE, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts

**CONFIDENTIAL: DO NOT SHARE****The Older the Better:****Are Elderly Study Participants More Nonrepresentative?**

Beatrice A. Golomb, MD, PhD \* †

Virginia T. Chan, MD \* ‡

Marcella A. Evans, BS \* ‡

Sabrina Koperski, BS \*

Halbert L. White, PhD ¶

Michael H. Criqui, MD, MPH \* †

\* Department of Medicine, University of California, San Diego

† Department of Family and Preventive Medicine, University of California, San Diego

‡ University of California, Irvine School of Medicine

¶ Department of Economics, University of California, San Diego

Running Title: Golomb 2012 - Elderly NonrepresentativeCorresponding Author & Reprint Requests:

Beatrice A. Golomb, MD, PhD

UCSD Department of Medicine

9500 Gilman Drive # 0995

La Jolla, CA 92093-0995 U.S.A

Phone: 858-558-4950 ext. 201

Fax: 858-558-4960

Email: [bgolomb@ucsd.edu](mailto:bgolomb@ucsd.edu)Word Count: 2,218

## Golomb 2012 – Elderly Nonrepresentative

**Abstract**

Objective: Study participants can differ from the target population they are taken to represent.

We sought to investigate whether older age magnifies such differences, examining age-trends, among study participants, in self-rated level of activity compared to others of the same age.

Design: Cross-sectional examination of the relation of participant age to reported “relative activity” (i.e. compared to others of the same age), a bidirectionally-correlated proxy for relative vitality, in exemplars of randomized and observational studies.

Setting: University of California, San Diego (UCSD)

Participants: 2,404 adults age 40-79 including employees of UCSD, and their partners (San Diego Population Study, observational study). 1,016 adults not on lipid medications and without known heart disease, diabetes, cancer or HIV (UCSD Statin Study, randomized trial).

Measurements: Self-rated activity relative to others one’s age, 5-point Likert Scale, was evaluated by age decade; and related via correlation and regression to a suite of health-relevant subjective and objective outcomes.

Results: Successively older participants reported successively greater activity relative to others their age (greater departure from the norm for their age),  $p < 0.001$  in both studies. Relative activity significantly predicted (in regression adjusted for age) actual activity (times/week exercised); and numerous self-rated and objective health-predictors. These included general self-rated health, CES-D (depression score), sleep, tiredness, energy; body mass index, waist circumference, serum glucose, HDL-cholesterol, triglycerides, and white blood cell count. Indeed some health-predictor associations with age in participants were “paradoxical,” consistent with greater apparent health in older age – for study participants.

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 Conclusion: Study participants may not be representative of the population they are intended to  
4  
5 reflect. Our results suggest that departures from representativeness may be amplified with  
6  
7 increasing subject age.  
8  
9

10 Trial Registration: UCSD Statin Study – Clinicaltrials.gov # NCT00330980

11 (<http://ClinicalTrials.gov>)

12  
13 **Keywords:** elderly; representativeness; sample selection; generalizability; clinical trials, subject  
14  
15 characteristics  
16  
17  
18

19 **Abbreviations:** UCSD – University of California, San Diego  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Relevance of data from human research studies to the general population depends on the similarity of study participants to those they are taken to represent, i.e. the “target” population. It is recognized that study samples may differ from the target population<sup>1 2</sup>. Often the study sample directly or disproportionately excludes the elderly<sup>3-5</sup> who have worse health and higher expected mortality<sup>6</sup>, and who may differ from younger participants in treatment effects.

Although there has been increasing emphasis (at least in principle) on inclusion of the elderly in studies<sup>7</sup>, there are reasons for concern that elderly study participants may be less representative of their age group than younger participants.

Self-selection by participants themselves of a relatively healthier and more functional study population may occur in all ages<sup>8-11</sup>, since even morbidity not requiring exclusion may nonetheless inhibit participation<sup>1</sup>. But since health problems and functional limitations that lead to self-exclusion may increasingly affect those older in age, we theorized that older age participants might be progressively less representative in indices relevant to function and vitality. Direct comparison of consenting participants to nonparticipants is problematic, since inherently the researcher has access only to the former group. Participants’ ratings of themselves relative to others their age provides a tentative approach to evaluate whether departures rise with age, if such relative measures can be validated against direct measures.

We validated “relative-activity,” that is, self-rated activity-level *compared to other individuals of the same age*, against an activity metric that is absolute (vs relative); and assessed its relation to health-relevant outcomes. We examined reported relative-activity, compared to other individuals ones age, from available exemplars of two types of medical studies

## Golomb 2012 – Elderly Nonrepresentative

(observational and randomized controlled trial) to evaluate whether reported departure from normative function rises with increasing participant age.

**Methods**Randomized Controlled Trial Participants:

1,016 male and female participants age 20-85 from the San Diego area were enrolled in the UCSD Statin Study, a double-blind, randomized, placebo-controlled trial assessing effects of statin cholesterol-lowering drugs on a relatively broadly sampled group of adults (a primary prevention sample). There was no imposed upper age limit. Participants were men over age 20 and surgically or chronologically postmenopausal women not on lipid medications and without extremes of LDL-cholesterol (high or low), diagnosed cardiovascular disease, diabetes or HIV. More information on study population and design is available elsewhere<sup>12</sup>.

Observational Study Participants:

2,404 selected men and women ages 40-79 were enrolled in the San Diego Population Study, a population-based observational study identifying prevalence of arterial and venous disease. Participants were drawn from current and former employees of the University of California San Diego (UCSD), as well as their spouses/ significant others – inclusion of which modestly extended the age range of participants in both directions<sup>13</sup>. In addition, a small number of non-UCSD volunteers were included. Participants represented a spectrum of socioeconomic status, including unemployed and retired as well as working persons. A full description of the study population is available elsewhere<sup>13</sup>.



## Golomb 2012 – Elderly Nonrepresentative

Both studies were approved by the UCSD Human Research Protections Program, and all participants gave informed consent to participate.

Relative Activity variable:

Participants in both studies were asked to rate their level of physical activity “Compared to other persons your age” on a 5-point Likert scale (1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active). We refer to this activity rating as “relative activity.” Single-item self-rated assessments have shown strong predictive validity<sup>14-16</sup>.

Validation Variables:

*Other measures used:* From the randomized trial, several other variables were chosen against which to validate the relative activity variable. All variables were assessed at baseline (prior to study treatment).

*Absolute activity:* We validated the relation of this relative activity measure to self-reported actual exercise frequency (number of episodes of vigorous exercise for at least 20 minutes over a week). Direct measurements of activity was not performed, but self-reported exercise-frequency related significantly to objective measures known to be affected by exercise (e.g. body mass index, triglycerides, HDL-cholesterol, each  $p < 0.001$ ) in age-sex adjusted analysis.

*Health Predictor Variables:* Self-rated and questionnaire variables known to predict mortality and health outcomes that were considered against *relative* activity included depressed mood (Center for Epidemiological Studies – Depression Scale aka CES-D, and self-rated), and single-item self-ratings of energy, tiredness, muscle weakness, fatigue with exertion, overall health, and

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 satisfaction with health. Objective measures included platelet count (acute phase reactant), white  
4  
5 blood count, serum glucose, HDL-cholesterol, triglycerides, body mass index (BMI), and waist  
6  
7 circumference.  
8  
9

### 10 11 12 Analyses:

13  
14  
15 Self-rated relative activity was tabulated by age decade. For each study, significance of  
16  
17 self-rated relative activity change with age assessed across the full age range. Activity  
18  
19 associations and health implications of the relative activity measure were examined in older  
20  
21 study participants (age > 50) from the randomized trial sample (in which these health variables  
22  
23 were assessed), using correlation; and also regression analysis. (Both by expectation and  
24  
25 empirically in this sample, people in their 30s and 40s were comparatively similar in their self-  
26  
27 rated relative activity, consistent with the expectation that age-related health conditions are not  
28  
29 yet strongly present, leading to the emphasis on those over age 50.) In the latter, age-relative  
30  
31 activity was the independent variable, and assessments were adjusted for actual age.  
32  
33  
34  
35

36  
37 For both study samples, we conducted bivariate analyses examining reported relative  
38  
39 activity level as a function of age decade. This was followed by multivariable regression using  
40  
41 ordinal logit with robust standard errors (aka White standard errors)<sup>17</sup> controlling for sex,  
42  
43 ethnicity (categorical variable) and education (scaled from 1=grade school or less to 9=doctoral  
44  
45 degree).  
46  
47

48  
49 All analyses were conducted using Stata™ version 8.0; StataCorp, College Station, Texas.  
50  
51 Two-sided P-values less than 0.05 were designated statistically significant.  
52  
53  
54

## 55 **Results**

56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 Self-reported activity relative to others ones age related strongly to actual activity:  
4  
5 (unadjusted) correlation 0.42,  $p < 0.0001$ ; (adjusted) regression beta (SE) 1.2 (0.092),  $p < 0.001$ .  
6  
7

8 Self-rated activity relative to others ones age also related strongly to multiple measures  
9  
10 known to predict health, healthcare utilization and mortality, such as general self-rated health,  
11  
12 energy, tiredness, depression (CES-D), sleep, muscular weakness, fatigue with exertion, and  
13  
14 metabolic syndrome factors of HDL, triglycerides, BMI, waist circumference and serum glucose  
15  
16  
17  
18 **(Table 1)**.  
19

20 Self-rated relative physical activity showed a graded positive relation to age on  
21  
22 unadjusted analysis ( $p < 0.001$ ) **(Table 2)**. This was true in both the clinical trial sample and the  
23  
24 observational study sample. Findings were monotonic in the observational sample, and nearly so  
25  
26 in the clinical trial sample for participants from their 40s to 80s.  
27  
28

29 Multivariable regression **(Table 3)** affirmed that a significant relation of age to reported  
30  
31 relative activity was retained with adjustment for variables (sex, ethnicity and education level)  
32  
33 that could relate to both age and activity of participants ( $p < 0.001$ ).  
34  
35  
36  
37  
38

## 39 **Discussion**

40  
41 To our knowledge this is the first explicit demonstration that progressively older study  
42  
43 participants may depart successively more from parity with those they are taken to represent, in  
44  
45 observational and clinical trial settings. This was found in exemplars of both observational  
46  
47 studies and clinical trials. Adults in their 30s and 40s reported being only modestly more active  
48  
49 than others their age (closest to “about as active” as others). By the oldest decades, participants  
50  
51 had surpassed the “somewhat more active” mark, even on average, and were partway, on average,  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 toward the maximum rating of “much more active” compared to others their age. These  
4  
5 differences by age were strongly significant.  
6  
7

8 This finding is concordant with expectations that might be generated from previous  
9  
10 observations linking study participation with higher health and vitality. All participants who self-  
11  
12 select for study participation may differ in systematic ways from the target population or  
13  
14 population as a whole<sup>8-11</sup>. Prior studies have noted that clinical trial participants are generally  
15  
16 younger and healthier than referred and registry patients<sup>4</sup>. Our results further show that  
17  
18 successively older participants *who do* participate in research studies may be successively less  
19  
20 typical of their age cohort in a metric with an expected – and indirectly observed – relation to  
21  
22 health. For instance, it related to general self-rated health, which has been found to strongly  
23  
24 predict physical function/disability, health care utilization, and mortality<sup>14-16</sup>. Relative activity  
25  
26 also related in expected directions to other assessed factors known to predict health and mortality  
27  
28 in elderly, such as fasting glucose<sup>18</sup>, white blood cell count<sup>19-21</sup>, HDL-cholesterol<sup>22</sup>, sleep  
29  
30 problems<sup>23,24</sup>, and depression<sup>25-31</sup>.  
31  
32  
33  
34  
35

36 Our evidence accords with and extends recent evidence from survey studies. Participants  
37  
38 who indicated (on a survey) they would volunteer for an exercise study reported less physical  
39  
40 function decline, more physical activity and less chronic pain than those who would not, as well  
41  
42 as worse self-reported health<sup>32</sup>; however, these reflect hypothetical intentions rather than  
43  
44 participation, and the fashion in which participants were shown to be differential focused largely  
45  
46 on domains that may affect comfort and performance for that study’s assessments. A survey  
47  
48 study of Finns aged 52-76 found that “Favorable health was generally more frequent among  
49  
50 respondents than nonrespondents,” gauging health status by medicine reimbursements  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 (ascertained by linking to register data)<sup>33</sup>. Whether disparities progressed successively as age  
4  
5 advanced was not ascertained.  
6  
7

8 Selective participation by healthier elderly has potential to influence trial outcomes. This  
9  
10 is particularly true for outcomes for which vitality, function, activity, or any of the range of  
11  
12 health-relevant correlates of relative activity, may serve as effect modifiers. (Such health  
13  
14 correlates include those elucidated here, and presumably many others that were not examined.)  
15  
16 The study also has relevance for outcomes for which differences in participants' activity and/or  
17  
18 function, through their relation to expected health, may modify study power. For example, a  
19  
20 doubling or halving of mortality by an intervention (or with a risk factor), even in the absence of  
21  
22 effect modification, will have lower statistical power in a sample with lower baseline risk of  
23  
24 mortality outcomes (as a healthier sample portends). Healthier elderly may reduce power for the  
25  
26 risk-side of the equation, which can shift the apparent risk-benefit balance.  
27  
28  
29  
30

31  
32 Limitations of the present analysis are several. Activity relative to others of the same age  
33  
34 was assessed by self-report. Objective evaluation of nonparticipants, to permit direct comparison,  
35  
36 is inherently problematic (as they have not consented to participate). This limitation is mitigated  
37  
38 by demonstration of strongly significant relationships of relative activity to health predictors  
39  
40 within the study population. (A relation to hard outcomes like mortality could not be assessed:  
41  
42 the observational study was not longitudinal, and the trial sample enrolled generally healthy  
43  
44 participants with only six-months follow-up.)  
45  
46  
47

48 It is possible that participants may over-represent their functional state relative to others;  
49  
50 but this would not produce an expected age association. In principle, older participants may  
51  
52 differ from younger participants in the manner of such amplification, but there is little reason to  
53  
54 believe this is the case, and the age-adjusted association of our relative activity measure to an  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 exercise frequency measure further diminishes this concern. There is reason to predict that as  
4  
5 limiting comorbidities and disabilities accrue with rising age, and as function and the ability to  
6  
7 sustain activity declines progressively with age, more elderly individuals will more often find  
8  
9 participation too burdensome – yielding a successively more rarefied sample that is progressively  
10  
11 more nonrepresentatively robust and healthy, compatible with the findings shown. Indeed, better  
12  
13 health has been reported to influence self-selection for participation in studies in general<sup>1</sup>, an  
14  
15 observation that might be predicted to drive the finding observed, since health problems increase  
16  
17 in prevalence with increasing age.  
18  
19  
20  
21

22 Factors driving self-selection for participation may vary depending on the character of the  
23  
24 study. Although theoretical considerations suggest our findings may generalize broadly, other  
25  
26 studies should evaluate how these findings are moderated based on the type of study and  
27  
28 condition being examined.  
29  
30  
31

32 One unsettling implication is that clinical guidelines lack a meaningful evidence basis,  
33  
34 when applied to those of older age. Concerns have previously been expressed that when  
35  
36 “evidence based” study findings *based on younger individuals* are implemented in elderly  
37  
38 patients with comorbidities, via clinical practice guidelines reinforced by performance pay, this  
39  
40 may result in perverse incentives that may diminish rather than enhance quality of care for  
41  
42 elderly<sup>34</sup>, by promoting promiscuous polypharmacy. Our findings suggest such concerns obtain  
43  
44 even when recommendations derive from data actually procured in elderly participants.  
45  
46  
47

48 (Analogous concerns may apply, irrespective of age, for patients with multiple comorbidities,  
49  
50 polypharmacy, dementia, disability, limited life expectancy, and/or past adverse responses to the  
51  
52 recommended treatment – groups that, like elderly, often bear less favorable risk-benefit  
53  
54 prospects.)  
55  
56  
57  
58  
59  
60

## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3  
4 For older elderly, some have urged a more individualized "less is more" approach placing  
5 greater emphasis on clinical judgment, quality of life, and in-depth consultation with the patient  
6 and family<sup>34-36</sup>. This seems rational, given 1) absence of applicable evidence that medication  
7  
8 benefits similarly apply, 2) increased medication burden, as age-related morbidities accrue, 3)  
9 amplified risk of drug adverse events, drug interactions and medication-taking errors in elderly  
10 with implications to quality of life and function, 4) magnified impact of added functional  
11 compromise in the elderly; coupled with 5) evidence, albeit non-randomized, suggesting striking  
12 subjective and objective benefits among elderly when systematic discontinuation of medications  
13 is undertaken<sup>35 36</sup>.

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25 In conclusion, as age advances, those who participate in clinical trials and observational  
26 studies may depart increasingly from those they are taken to represent. That is, real patients may  
27 depart increasingly from (an ever more rarefied, nonrepresentative, healthiest subsegment of) the  
28 elderly population that volunteers to participate in clinical studies, rendering study findings of  
29 increasingly doubtful applicability. This magnifies concerns that, as the elderly swell as a  
30 fraction of the population the chasm may grow, between what is recommended based on  
31 "evidence," and what is best for the patient.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The UCSD Statin Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, RO1 HL63055 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. The San Diego Population Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, grant RO1 53487 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. We gratefully thank the staff and participants from both the UCSD Statin Study and the San Diego Population Study; and the staff from the UCSD GCRC.

## Disclaimers

Competing Interest Statement: *All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare that all authors have no relationships with any companies that might have an interest in the submitted work in the previous 3 years; nor do their spouses, partners, or children have any financial relationships that may be relevant to the submitted work; and none of the authors have any non-financial interests that may be relevant to the submitted work.*

Financial Support: NHLBI RO1 HL63055; NHLBI RO1 HL53487 and, NIH General Clinical Research Center Program grant MO1 RR0827. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of this report.

Author Contributions: Golomb was PI on the randomized trial, provided the concept, and generated the initial draft. Chan worked with Golomb to perform initial analyses and early



## Golomb 2012 – Elderly Nonrepresentative

1  
2  
3 revisions to the manuscript. Criqui was PI on the observational study, co-PI on the randomized  
4 trial, and provided access to the observational data. White provided senior statistical oversight and  
5  
6 conceptual and editorial input. Evans conducted literature reviews on risk factors and worked  
7  
8 with Golomb on an intermediate set of revisions. Koperski created Stata do-files, replicated the  
9  
10 findings, reviewed all findings for correctness with Golomb, and performed editorial and  
11  
12 administrative aspects of submission. All authors reviewed the manuscript for intellectual content.  
13  
14

15 Data Sharing: Technical appendix, statistical code, and dataset available from the corresponding  
16  
17 author ([bgolomb@ucsd.edu](mailto:bgolomb@ucsd.edu)).  
18  
19

20  
21 Exclusive Licence: The Corresponding Author has the right to grant on behalf of all authors and  
22  
23 does grant on behalf of all authors, an exclusive licence (or non exclusive for government  
24  
25 employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit  
26  
27 this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and  
28  
29 sublicences to exploit all subsidiary rights, as set out in our licence  
30  
31  
32

33  
34 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Ganguli M, Lytle ME, Reynolds MD, et al. Random versus volunteer selection for a community-based study. *J Gerontol A Biol Sci Med Sci* 1998;53(1):M39-46.
2. Kennedy WA, Laurier C, Malo JL, et al. Does clinical trial subject selection restrict the ability to generalize use and cost of health services to "real life" subjects? *Int J Technol Assess Health Care* 2003;19(1):8-16.
3. Swenson WM. Sample selection bias in clinical research. *Psychosomatics* 1980;21(4):291-2.
4. Kaiser C, Jeger R, Wyrsh S, et al. Selection bias of elderly patients with chronic angina referred for catheterization. *Int J Cardiol* 2006;110(1):80-5.
5. Turazza FM, Franzosi MG. Is anticoagulation therapy underused in elderly patients with atrial fibrillation? *Drugs Aging* 1997;10(3):174-84.
6. Fernandez-Merino MC, Rey-Garcia J, Tato A, et al. [Self-perception of health and mortality in elderly from a rural community]. *Aten Primaria* 2000;25(7):459-63.
7. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. *Intern Med J* 2006;36(4):216-20.
8. Bornehag CG, Sundell J, Sigsgaard T, et al. Potential self-selection bias in a nested case-control study on indoor environmental factors and their association with asthma and allergic symptoms among pre-school children. *Scand J Public Health* 2006;34(5):534-43.
9. Antman K, Amato D, Wood W, et al. Selection bias in clinical trials. *J Clin Oncol* 1985;3(8):1142-7.
10. Sugisawa H, Kishino H, Sugihara Y, et al. [Comparison of characteristics between respondents and nonrespondents in a national survey of Japanese elderly using six year follow-up study]. *Nippon Kosho Eisei Zasshi* 1999;46(7):551-62.
11. Sugisawa H, Kishino H, Sugihara Y, et al. [Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly]. *Nippon Kosho Eisei Zasshi* 2000;47(4):337-49.
12. Golomb BA, Criqui MH, White HL, et al. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. *Control Clin Trials* 2004;25(2):178-202.
13. Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. *Am J Epidemiol* 2003;158(5):448-56.
14. DeSalvo KB, Bloser N, Reynolds K, et al. Mortality prediction with a single general self-rated health question. A meta-analysis. *J Gen Intern Med* 2006;21(3):267-75.
15. DeSalvo KB, Fan VS, McDonnell MB, et al. Predicting mortality and healthcare utilization with a single question. *Health Serv Res* 2005;40(4):1234-46.
16. DeSalvo KB, Fisher WP, Tran K, et al. Assessing measurement properties of two single-item general health measures. *Qual Life Res* 2006;15(2):191-201.
17. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. *Econometrica* 1980;48:817-38.
18. Simons LA, Friedlander Y, McCallum J, et al. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. *Aust N Z J Med* 2000;30(1):41-7.
19. Jee SH, Park JY, Kim HS, et al. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. *Am J Epidemiol* 2005;162(11):1062-9.

## Golomb 2012 – Elderly Nonrepresentative

20. de Labry LO, Campion EW, Glynn RJ, et al. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. *J Clin Epidemiol* 1990;43(2):153-7.
21. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. *J Clin Epidemiol* 2001;54(3):316-22.
22. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons [see comments]. *Jama* 1995;274(7):539-44.
23. Lan TY, Lan TH, Wen CP, et al. Nighttime sleep, Chinese afternoon nap, and mortality in the elderly. *Sleep* 2007;30(9):1105-10.
24. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. *J Intern Med* 2002;251(3):207-16.
25. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Archives of Internal Medicine* 2001;161(15):1849-56.
26. Blazer DG, Hybels CF, Pieper CF. The association of depression and mortality in elderly persons: a case for multiple, independent pathways. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2001;56(8):M505-9.
27. Dubielzig RR, Hawkins KL, Miller PE. Myofibroblastic sarcoma originating at the site of rabies vaccination in a cat. *J Vet Diagn Invest* 1993;5(4):637-8.
28. Hendrick MJ, Dunagan CA. Focal necrotizing granulomatous panniculitis associated with subcutaneous injection of rabies vaccine in cats and dogs: 10 cases (1988-1989). *J Am Vet Med Assoc* 1991;198(2):304-5.
29. Peters R, Pinto E, Beckett N, et al. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing* 2010;39(4):439-45.
30. Janzing JG, Bouwens JM, Teunisse RJ, et al. The relationship between depression and mortality in elderly subjects with less severe dementia. *Psychological Medicine* 1999;29(4):979-83.
31. Gruffydd-Jones TJ, Sparkes AH. Vaccination and fibrosarcomas in cats. *Vet Rec* 1994;134(12):310.
32. de Souto Barreto P, Ferrandez AM, Saliba-Serre B. Are Older Adults Who Volunteer to Participate in an Exercise Study Fitter and Healthier than Non-Volunteers? The participation bias of the study population. *J Phys Act Health* 2012.
33. Nummela O, Sulander T, Helakorpi S, et al. Register-based data indicated nonparticipation bias in a health study among aging people. *J Clin Epidemiol* 2011;64(12):1418-25.
34. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA* 2005;294(6):716-24.
35. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. *Arch Intern Med* 2010;170(18):1648-54.

## Golomb 2012 – Elderly Nonrepresentative

- 1  
2  
3 36. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective  
4 geriatric-palliative approach for improving drug therapy in disabled elderly people. *Isr*  
5 *Med Assoc J* 2007;9(6):430-4.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Golomb 2012 – Elderly Nonrepresentative

Table 1. Self-Rated “Relative Activity”<sup>\*</sup> Relates to Health-Predictors (Age >50)

Variable	Correlation Coefficient	P-value	Regression Coefficient, age adjusted <sup>†</sup>	P-value	Age Relation, sign and P-value
Times/wk exercise at least 20minutes	0.42	<0.0001	1.2 (0.092)	<0.001	(-) 0.024
CES-D (0-52)	-0.21	<0.0001	-1.3 (0.23)	<0.001	NS
Depressed (0-10)	-0.13	0.0083	-0.21 (0.086)	0.017	NS
Energy (0-10)	0.21	<0.0001	0.34 (0.064)	<0.001	(+) 0.031
Sleep problems (0-10)	-0.084	0.028	-0.21 (.095)	0.024	NS
Sleep quality (0-30)	0.078	0.036	0.037 (0.011)	0.001	(+) 0.081
Tired (0-10)	-0.29	<0.0001	-0.72 (0.13)	<0.001	(+) 0.001
Muscle weakness	-0.14	<0.0001	-0.29 (0.070)	<0.001	(+) 0.005
Fatigue w Exertion (0-10)	-0.26	<0.0001	-0.61 (0.12)	<0.001	(+) 0.002
Health (0-10)	0.20	<0.0001	0.31 (0.061)	<0.001	(+) 0.071
Satisfaction with health (0-100)	0.30	<0.0001	5.6 (0.69)	<0.001	NS
Glucose (mg/dL) ‡	-0.073	0.049	-0.73 (0.31)	0.019	(+) 0.014
HDL (mg/dL)	0.10	0.0063	1.2 (0.53)	0.028	(+) 0.001
Triglycerides (mg/dL)	-0.17	<0.0001	-10 (2.3)	<0.001	NS
Body mass index	-0.26	<0.0001	-0.97 (0.15)	<0.001	(-) 0.002
Waist (cm)	-0.23	<0.0001	-3.9 (0.63)	<0.001	NS
Platelets	-0.073	0.051	-2.7 (1.7)	0.11	(-) 0.043
White blood cell count	-0.08	0.027	-0.125 (0.050)	+0.012	(+) 0.058

CES-D – Center for Epidemiological Studies -Depression scale, HDL – high density lipoprotein cholesterol, NS – non-significant.

\* Level of activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.

† Regression examines relative activity level relation to health predictor, among those age > 50, with age as an adjusted covariate in the regressions.

(The column to the far right gives the sign of the coefficient for the age variable, and its significance.)

‡ Note: patients with diabetes or measured glucose over 142 were excluded. This finding is thus despite range restriction.

Note that in these study participants, there is a “paradoxically” favorable age association for some variables that generally worsen with rising age, including energy, sleep quality, health, and HDL-cholesterol.

Table 2. “Relative-Activity” Ratings\*, by Age

	Clinical Trial Sample		Observational Sample	
Age Decade	N	Relative Activity* Mean (SD)	N	Relative Activity* Mean (SD)
30s	80	3.35 (1.02)	34	3.26 (1.24)
40s	180	3.30 (1.20)	565	3.27 (1.23)
50s	308	3.49 (1.20)	650	3.68 (1.15)
60s	261	3.92 (1.07)	569	3.94 (1.05)
70s	151	3.89 (1.01)	512	3.97 (1.04)
80s	20	4.10 (1.07)	24	4.17 (1.31)
Significance of Change by Age Decade		P < 0.001		P < 0.001

N – Number; SD – Standard deviation

\* Level of physical activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.

Golomb 2012 – Elderly Nonrepresentative

**Table 3. Older Participant Age Associated with Greater Self-reported “Relative-Activity”\*, Ordinal Logit Analyses**

	Clinical Trial Sample				Observational Sample			
	Coefficient for Age Decade	Standard Error	P-value	95% CI	Coefficient for Age Decade	Standard Error	P-value	95% CI
<b>Unadjusted</b>	0.29	0.044	<0.001	0.21, 0.38	0.37	0.034	<0.001	0.31, 0.44
<b>Multivariable adjusted†</b>	0.35	0.052	<0.001	0.25, 0.45	0.37	0.035	<0.001	0.30, 0.44

CI – Confidence interval

\* Level of activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.

†Ordinal logit adjusted for age, gender, ethnicity, and education level.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**CONFIDENTIAL: DO NOT SHARE**

**The Older the Better:**

**Are Elderly Study Participants More Nonrepresentative?**

Beatrice A. Golomb, MD, PhD \* †

Virginia T. Chan, MD \* ‡

Marcella A. Evans, BS \* ‡

Sabrina Koperski, BS \*

Halbert L. White, PhD ¶

Michael H. Criqui, MD, MPH \* †

\* Department of Medicine, University of California, San Diego

† Department of Family and Preventive Medicine, University of California, San Diego

‡ University of California, Irvine School of Medicine

¶ Department of Economics, University of California, San Diego

Running Title: Golomb 2012 - Elderly Nonrepresentative

Corresponding Author & Reprint Requests:

Beatrice A. Golomb, MD, PhD

UCSD Department of Medicine

9500 Gilman Drive # 0995

La Jolla, CA 92093-0995 U.S.A

Phone: 858-558-4950 ext. 201

Fax: 858-558-4960

Email: [bgolomb@ucsd.edu](mailto:bgolomb@ucsd.edu)


Word Count: 2,218



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Golomb 2012 – Elderly Nonrepresentative

For peer review only



## Golomb 2012 – Elderly Nonrepresentative

**Abstract**

**Objective:** Study ~~subjects~~participants can differ from the target population they are taken to represent. ~~We sought to investigate whether age modifies such differences~~We sought to [investigate whether older age magnifies such differences, examining age-trends, among study participants, in self-rated level of activity compared to others of the same age, in terms of relative activity](#)~~investigate whether age modifies such differences.~~

**Design:** Cross-sectional examination of the relation of [participant](#) age to reported “relative activity” ([i.e.](#) compared to others of the same age), a bidirectionally-correlated proxy for relative vitality, in exemplars of randomized and observational studies.

**Setting:** University of California, San Diego (UCSD)

**Participants:** 2,404 adults age 40-79 including employees of UCSD, and their partners (San Diego Population Study, observational study). 1,016 adults not on lipid medications and without known heart disease, diabetes, cancer or HIV (UCSD Statin Study, randomized trial).

**Measurements:** Self-rated activity relative to others one’s age, 5-point Likert Scale, was evaluated by age decade; and related via correlation and regression to a suite of health-relevant subjective and objective outcomes.

**Results:** Successively older participants reported successively greater activity relative to others their age (greater departure from the norm for their age),  $p < 0.001$  in both studies. Relative activity significantly predicted (in regression adjusted for age) actual activity (times/week exercised); and numerous self-rated and objective health-predictors. These included general self-rated health, CES-D (depression score), sleep, tiredness, energy; body mass index, waist circumference, serum glucose, HDL-cholesterol, triglycerides, and white blood cell count.

Golomb 2012 – Elderly Nonrepresentative

Indeed some health-predictor associations with age in participants were “paradoxical,” consistent with greater apparent health in older age – for study participants.

Conclusion: Study participants may not be representative of the population they are intended to reflect. Our results suggest that departures from representativeness may be amplified with increasing subject age.

Trial Registration: UCSD Statin Study – Clinicaltrials.gov # NCT00330980

(<http://ClinicalTrials.gov>)

**Keywords:** elderly; representativeness; sample selection; generalizability; [clinical trials](#), [subject characteristics](#)

**Abbreviations:** UCSD – University of California, San Diego

**What this paper adds:**

**Section 1—What is already known about the subject?**

~~Study participants differ from the general population they are taken to represent and may be healthier.~~

**Section 2—What this study adds**

~~This study demonstrated that with increasing age, self-selected study participants diverge increasingly from the population they are taken to represent. This has implications for studies of, and including, elderly subjects; affecting generalizability to older real-world populations.~~

## Golomb 2012 – Elderly Nonrepresentative

**Introduction**

Relevance of data from human research studies to the general population depends on the similarity of study participants to those they are taken to represent, i.e. the “target” population. It is recognized that study samples may differ from the target population<sup>1,2</sup>. Often the study sample directly or disproportionately excludes the elderly<sup>3-5</sup> who have worse health and higher expected mortality<sup>6</sup>, and who may differ from younger [subjects/participants](#) in treatment effects.

Although there has been increasing emphasis (at least in principle) on inclusion of the elderly in studies<sup>7</sup>, there are reasons for concern that elderly study participants may be less representative of their age group than younger [subjects/participants](#).

Self-selection by [subjects/participants](#) themselves of a relatively healthier and more functional study population may occur in all ages<sup>8-11</sup>, since even morbidity not requiring exclusion may nonetheless inhibit participation<sup>1</sup>. But since health problems and functional limitations that lead to self-exclusion may increasingly affect those older in age, we theorized that older age participants might be progressively less representative in indices relevant to function and vitality. Direct comparison of consenting participants to nonparticipants is problematic, since inherently the researcher has access only to the former group.

[Subjects/Participants](#)’ ratings of themselves relative to others their age provides a tentative approach to evaluate whether departures rise with age, if such relative measures can be validated against direct measures.

We validated “relative-activity,” [that is, self-rated activity-level compared to other individuals ~~ones age of the same age~~](#), against an activity metric that is absolute (vs relative); and assessed its relation to health-relevant outcomes. We examined reported relative-activity, compared to other individuals ~~ones age~~, from available exemplars of two types of medical

## Golomb 2012 – Elderly Nonrepresentative

studies (observational and randomized controlled trial) to evaluate whether reported departure from normative function rises with increasing participant age.

### Methods

#### Randomized Controlled Trial Subjects/Participants:

1,016 male and female subjects/participants age 20-85 from the San Diego area were enrolled in the UCSD Statin Study, a double-blind, randomized, placebo-controlled trial assessing effects of statin cholesterol-lowering drugs on a relatively broadly sampled group of adults (a primary prevention sample). There was no imposed upper age limit.

Subjects/Participants were men over age 20 and ~~nonprocreative surgically or chronologically postmenopausal~~ women not on lipid medications and without extremes of LDL-cholesterol (high or low), diagnosed cardiovascular disease, diabetes or HIV. More information on study population and design is available elsewhere<sup>12</sup>.

#### Observational Study Subjects/Participants:

2,404 selected men and women ages 40-79 were enrolled in the San Diego Population Study, a population-based observational study identifying prevalence of arterial and venous disease. Subjects/Participants were drawn from current and former employees of the University of California San Diego (UCSD), as well as their spouses/ significant others – inclusion of which modestly extended the age range of participants in both directions<sup>13</sup>. In addition, a small number of non-UCSD volunteers were included. Subjects/Participants represented a spectrum of socioeconomic status, including unemployed and retired as well as working persons. A full description of the study population is available elsewhere<sup>13</sup>.

## Golomb 2012 – Elderly Nonrepresentative

Both studies were approved by the UCSD Human Research Protections Program, and all subjects/participants gave informed consent to participate.

Relative Activity variable:

Participants in both studies were asked to rate their level of physical activity “Compared to other persons your age”. In both studies, “activity relative compared to others your age” was queried at baseline and measured on a 5-point Likert scale (1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active). We refer to this activity rating as “relative activity.” Single-item self-rated assessments have shown strong predictive validity<sup>14-16</sup>.

Validation Variables:

*Other measures used:* From the randomized trial, several other variables were chosen against which to validate the relative activity variable. [All variables were assessed at baseline \(prior to study treatment\).](#)

*Absolute activity:* We validated the relation of this relative activity measure to self-reported actual exercise frequency (number of episodes of vigorous exercise for at least 20 minutes over a week). [Direct measurements of activity was not performed, but self-reported exercise-frequency related significantly to objective measures known to be affected by exercise \(e.g. body mass index, triglycerides, HDL-cholesterol, each  \$p<0.001\$ \) in age-sex adjusted analysis\).](#)

*Health Predictor Variables:* Self-rated and questionnaire variables known to predict mortality and health outcomes that were considered against *relative* activity included depressed mood

### Golomb 2012 – Elderly Nonrepresentative

(Center for Epidemiological Studies – Depression Scale aka CES-D, and self-rated), and single-item self-ratings of energy, tiredness, muscle weakness, fatigue with exertion, overall health, and satisfaction with health. Objective measures included platelet count (acute phase reactant), white blood count, serum glucose, HDL-cholesterol, triglycerides, body mass index (BMI), and waist circumference.

#### Analyses:

Self-rated relative activity was tabulated by age decade. For each study, significance of self-rated relative activity change with age assessed across the full age range. Activity associations and health implications of the relative activity measure were examined in older study participants (age > 50) from the randomized trial sample (in which these health variables were assessed), using correlation; and also regression analysis. (Both by expectation and empirically in this sample, people in their 30s and 40s were comparatively similar in their self-rated relative activity, consistent with the expectation that age-related health conditions are not yet strongly present, leading to the emphasis on those over age 50.) In the latter, age-relative activity was the independent variable, and assessments were adjusted for actual age.

For both study samples, we conducted bivariate analyses examining reported relative activity level as a function of age decade. This was followed by multivariable regression using ordinal logit with robust standard errors (aka White standard errors)<sup>17</sup> controlling for sex, ethnicity (categorical variable) and education (scaled from 1=grade school or less to 9=doctoral degree).

All analyses were conducted using Stata™ version 8.0; StataCorp, College Station, Texas. Two-sided P-values less than 0.05 were designated statistically significant.

## Golomb 2012 – Elderly Nonrepresentative

**Results**

Self-reported activity relative to others ones age related strongly to actual activity: (unadjusted) correlation 0.42,  $p < 0.0001$ ; (adjusted) regression beta (SE) 1.2 (0.092),  $p < 0.001$ .

Self-rated activity relative to others ones age also related strongly to multiple measures known to predict health, healthcare utilization and mortality, such as general self-rated health, energy, tiredness, depression (CES-D), sleep, muscular weakness, fatigue with exertion, and metabolic syndrome factors of HDL, triglycerides, BMI, waist circumference and serum glucose (Table 1).

Self-rated relative physical activity showed a graded positive relation to age on unadjusted analysis ( $p < 0.001$ ) (Table 2). This was true in ~~each~~ both the clinical trial sample and the observational study sample. Findings were monotonic in the observational sample, and nearly so in the clinical trial sample for ~~subjects~~ participants from their 40s to 80s.

Multivariable regression (Table 3) affirmed that a significant relation of age to reported relative activity was retained with adjustment for variables (sex, ethnicity and education level) that could relate to both age and activity of participants ( $p < 0.001$ ).

**Discussion**

To our knowledge this is the first explicit demonstration that progressively older study ~~subjects~~ participants may depart successively more from parity with those they are taken to represent, in observational and clinical trial settings. This was found in exemplars of both



### Golomb 2012 – Elderly Nonrepresentative

observational studies and clinical trials. Adults in their 30s and 40s reported being only modestly more active than others their age (closest to “about as active” as others). By the oldest decades, participants had surpassed the “somewhat more active” mark, even on average, and were partway, on average, toward the maximum rating of “much more active” compared to others their age. These differences by age were strongly significant.

This finding is concordant with expectations that might be generated from previous observations linking study participation with higher health and vitality. All [subjects/participants](#) who self-select for study participation may differ in systematic ways from the target population or population as a whole<sup>8-11</sup>. Prior studies have noted that clinical trial participants are generally younger and healthier than referred and registry patients<sup>4</sup>. Our results further show that successively older [subjects/participants](#) who do participate in research studies may be successively less typical of their age cohort in a metric with an expected – and indirectly observed – relation to health. For instance, it related to general self-rated health, which has been found to strongly predict physical function/disability, health care utilization, and mortality<sup>14-16</sup>. Relative activity also related in expected directions to other assessed factors known to predict health and mortality in elderly, such as fasting glucose<sup>18</sup>, white blood cell count<sup>19-21</sup>, HDL-cholesterol<sup>22</sup>, sleep problems<sup>23-24</sup>, and depression<sup>25-31</sup>.

[Our evidence accords with and extends recent evidence from survey studies.](#)

[Subjects/Participants who indicated \(on a survey\) they would volunteer for an exercise study reported less physical function decline, more physical activity and less chronic pain than those who would not, as well as worse self-reported health<sup>32</sup>; however, these reflect hypothetical intentions rather than participation, and the fashion in which \[subjects/participants\]\(#\) were shown to be differential focused largely on domains that may affect comfort and performance for that](#)

## Golomb 2012 – Elderly Nonrepresentative

[study's assessments. A survey study of Finns aged 52-76 found that "Favorable health was generally more frequent among respondents than nonrespondents," gauging health status by medicine reimbursements \(ascertained by linking to register data\)<sup>33</sup>. Whether disparities progressed successively as age advanced was not ascertained.](#)

Selective participation by healthier elderly has potential to influence trial outcomes. This is particularly true for outcomes for which vitality, function, activity, or any of the range of health-relevant correlates of relative activity, may serve as effect modifiers. (Such health correlates include those elucidated here, and presumably many others that were not examined.)

The study also has relevance for outcomes for which differences in [subjects/participants'](#) activity and/or function, through their relation to expected health, may modify study power. For example, a doubling or halving of mortality by an intervention (or with a risk factor), even in the absence of effect modification, will have lower statistical power in a sample with lower baseline risk of mortality outcomes (as a healthier sample portends). Healthier elderly may reduce power for the risk-side of the equation, which can shift the apparent risk-benefit balance.

Limitations of the present analysis are several. Activity relative to others of the same age was assessed by self-report. Objective evaluation of nonparticipants, to permit direct comparison, is inherently problematic (as they have not consented to participate). This limitation is mitigated by demonstration of strongly significant relationships of relative activity to health predictors within the study population. (A relation to hard outcomes [like mortality](#) could not be assessed: the observational study was not longitudinal, and the trial sample enrolled generally healthy participants with only six-months follow-up.)

It is possible that [subjects/participants](#) may over-represent their functional state relative to others; but this would not produce an expected age association. In principle, older

## Golomb 2012 – Elderly Nonrepresentative

[subjects/participants](#) may differ from younger [subjects/participants](#) in the manner of such amplification, but there is little reason to believe this is the case, and the age-adjusted association of our relative activity measure to an exercise frequency measure further diminishes this concern. There is reason to predict that as limiting comorbidities and disabilities accrue with rising age, and as function and the ability to sustain activity declines progressively with age, more elderly individuals will more often find participation too burdensome – yielding a successively more rarefied sample that is progressively more nonrepresentatively robust and healthy, compatible with the findings shown. Indeed, better health has been reported to influence self-selection for participation in studies in general<sup>1</sup>, an observation that might be predicted to drive the finding observed, since health problems increase in prevalence with increasing age.

Factors driving self-selection for participation may vary depending on the character of the study. Although theoretical considerations suggest our findings may generalize broadly, other studies should evaluate how these findings are moderated based on the type of study and condition being examined.

[One unsettling implication is that clinical guidelines lack a meaningful evidence basis, when applied to those of older age. Concerns have previously been expressed that when “evidence based” study findings based on younger individuals are implemented in elderly patients with comorbidities, via clinical practice guidelines reinforced by performance pay, this may result in perverse incentives that may diminish rather than enhance quality of care for elderly<sup>34</sup>, by promoting promiscuous polypharmacy. Our findings suggest such concerns obtain even when recommendations derive from data actually procured in elderly participants. \(Analogous concerns may apply, irrespective of age, for patients with multiple comorbidities, polypharmacy, dementia, disability, limited life expectancy, and/or past adverse responses to the](#)

## Golomb 2012 – Elderly Nonrepresentative

recommended treatment – groups that, like elderly, often bear less favorable risk-benefit prospects.)

For older elderly, some have urged a more individualized "less is more" approach placing greater emphasis on clinical judgment, quality of life, and in-depth consultation with the patient and family<sup>34-36</sup>. This seems rational, given 1) absence of applicable evidence that medication benefits similarly apply, 2) increased medication burden, as age-related morbidities accrue, 3) amplified risk of drug adverse events, drug interactions and medication-taking errors in elderly with implications to quality of life and function, 4) magnified impact of added functional compromise in the elderly; coupled with 5) evidence, albeit non-randomized, suggesting striking subjective and objective benefits among elderly when systematic discontinuation of medications is undertaken<sup>35 36</sup>.

In conclusion, as ~~subject~~ age advances, those who participate in clinical trials and observational studies may depart increasingly from those they are taken to represent, ~~in physical activity and, likely, in health~~. That is, ~~real patients may depart increasingly from (an ever more rarefied, nonrepresentative, healthiest subsegment of) the elderly population that volunteers to participate in clinical studies~~ trial subjects, rendering study findings of increasingly doubtful applicability. This magnifies concerns that, as the elderly swell as a fraction of the population, ~~the s~~. Our finding has fundamental implications for how results in elderly study participants may reflect on elderly more generally, implications which rise in importance as the population continues to age, ~~correspondingly larger disparities~~ chasm may grow, between what is recommended based on "evidence," and ~~treatment realities may~~ what is best for the patient. ~~be expected~~

## Golomb 2012 – Elderly Nonrepresentative

Both studies compared were designed to assess physical activity and health parameters in what can be defined as prevention, observational studies. The proven "lack of representativeness" would probably be even more significant in studies evaluating or comparing therapies for existing diseases.

Under representation of the elderly in clinical studies is a well accepted fact; several authors warn against automatic implementation of clinical practice guidelines (CPGs) based on EBM studies proving a positive benefit/risk ratio in younger adults, to the elderly. Boyd et al (Boyd) concluded that such implementation "could lead to inappropriate judgment of the care provided to older individuals,...create perverse incentives that emphasize the wrong aspects of care for this population and diminish the quality of their care". The present study further emphasizes that even when elders are included in studies, they do not represent the entire elderly population and we should be very cautious while interpreting the results. For most CPGs, EBM proving a positive benefit/risk ratio is lacking, in correlation to old age, co-morbidity, disability, dementia and limited life expectancy. For these rapidly increasing sub populations, it may be reasonable to adopt a completely different

- indiv

idualized, "less is more" approach as suggested by Garfinkel, while giving more place to clinical judgment, quality of life and in depth consultation with the patient and family (Garfinkel 2010, Garfinkel 2007).

## Golomb 2012 – Elderly Nonrepresentative

**Acknowledgements**

The UCSD Statin Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, RO1 HL63055 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. The San Diego Population Study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, grant RO1 53487 and National Institutes of Health General Clinical Research Center Program grant MO1 RR0827. We gratefully thank the staff and ~~subjects~~participants from both the UCSD Statin Study and the San Diego Population Study; and the staff from the UCSD GCRC.

**Disclaimers**

Competing Interest Statement: *All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare that all authors have no relationships with any companies that might have an interest in the submitted work in the previous 3 years; nor do their spouses, partners, or children have any financial relationships that may be relevant to the submitted work; and none of the authors have any non-financial interests that may be relevant to the submitted work.*

Financial Support: NHLBI RO1 HL63055; NHLBI RO1 HL53487 and, NIH General Clinical Research Center Program grant MO1 RR0827. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of this report.

Author Contributions: [Golomb was PI on the randomized trial, provided the concept, and generated the initial draft. Chan worked with Golomb to perform initial analyses and early](#)

## Golomb 2012 – Elderly Nonrepresentative

revisions to the manuscript. Criqui was PI on the observational study, co-PI on the randomized trial, and provided access to the observational data. White provided senior statistical oversight and conceptual and editorial input. Evans conducted literature reviews on risk factors and worked with Golomb on an intermediate set of revisions. Koperski created Stata do-files, replicated the findings, reviewed all findings for correctness with Golomb, and performed editorial and administrative aspects of submission. All authors reviewed the manuscript for intellectual content. Dr. Golomb was PI on the randomized trial, had the idea, and generated the initial draft. Dr. Chan with Dr. Golomb performed initial analyses and early revisions to the manuscript. Dr. Criqui was PI on the observational study, co-PI on the randomized trial, and provided access to the observational data. Dr. White, study statistician, provided senior statistical oversight. Marcella Evans conducted literature reviews related to health predictors, and worked with Dr. Golomb to revise to the manuscript. Sabrina Koperski created Stata do files for replication of findings, replicated the findings, reviewed all findings for correctness with Dr. Golomb, and performed the administrative aspects of submission. All authors reviewed the manuscript for intellectual content and provided conceptual and editorial input. All authors, external and internal, had full access to all of the data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors certify that this manuscript represents valid work and has not been published or is currently under consideration for publication elsewhere.

Data Sharing: Technical appendix, statistical code, and dataset available from the corresponding author (bgolomb@ucsd.edu).


Exclusive Licence: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Golomb 2012 – Elderly Nonrepresentative**

this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

For peer review only





## Golomb 2012 – Elderly Nonrepresentative

## References

1. Ganguli M, Lytle ME, Reynolds MD, Dodge HH. Random versus volunteer selection for a community-based study. *J Gerontol A Biol Sci Med Sci* 1998;53(1):M39-46.
2. Kennedy WA, Laurier C, Malo JL, Ghezzi H, L'Archeveque J, Contandriopoulos AP. Does clinical trial subject selection restrict the ability to generalize use and cost of health services to "real life" subjects? *Int J Technol Assess Health Care* 2003;19(1):8-16.
3. Swenson WM. Sample selection bias in clinical research. *Psychosomatics* 1980;21(4):291-2.
4. Kaiser C, Jeger R, Wyrsh S, Schoeb L, Kuster GM, Buser P, et al. Selection bias of elderly patients with chronic angina referred for catheterization. *Int J Cardiol* 2006;110(1):80-5.
5. Turazza FM, Franzosi MG. Is anticoagulation therapy underused in elderly patients with atrial fibrillation? *Drugs Aging* 1997;10(3):174-84.
6. Fernandez-Merino MC, Rey-Garcia J, Tato A, Beceiro F, Barros-Dios J, Gude F. [Self-perception of health and mortality in elderly from a rural community]. *Aten Primaria* 2000;25(7):459-63.
7. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. *Intern Med J* 2006;36(4):216-20.
8. Bornehag CG, Sundell J, Sigsgaard T, Janson S. Potential self-selection bias in a nested case-control study on indoor environmental factors and their association with asthma and allergic symptoms among pre-school children. *Scand J Public Health* 2006;34(5):534-43.
9. Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, et al. Selection bias in clinical trials. *J Clin Oncol* 1985;3(8):1142-7.
10. Sugisawa H, Kishino H, Sugihara Y, Okabayashi H, Shibata H. [Comparison of characteristics between respondents and nonrespondents in a national survey of Japanese elderly using six year follow-up study]. *Nippon Koshu Eisei Zasshi* 1999;46(7):551-62.
11. Sugisawa H, Kishino H, Sugihara Y, Shibata H. [Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly]. *Nippon Koshu Eisei Zasshi* 2000;47(4):337-49.
12. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. *Control Clin Trials* 2004;25(2):178-202.
13. Criqui MH, Jamosmos M, Fronck A, Denenberg JO, Langer RD, Bergan J, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. *Am J Epidemiol* 2003;158(5):448-56.
14. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. *J Gen Intern Med* 2006;21(3):267-75.
15. DeSalvo KB, Fan VS, McDonnell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. *Health Serv Res* 2005;40(4):1234-46.
16. DeSalvo KB, Fisher WP, Tran K, Bloser N, Merrill W, Peabody J. Assessing measurement properties of two single-item general health measures. *Qual Life Res* 2006;15(2):191-201.
17. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. *Econometrica* 1980;48:817-38.
18. Simons LA, Friedlander Y, McCallum J, Simons J. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. *Aust N Z J Med* 2000;30(1):41-7.

## Golomb 2012 – Elderly Nonrepresentative

19. Jee SH, Park JY, Kim HS, Lee TY, Samet JM. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. *Am J Epidemiol* 2005;162(11):1062-9.
20. de Labry LO, Campion EW, Glynn RJ, Vokonas PS. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. *J Clin Epidemiol* 1990;43(2):153-7.
21. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. *J Clin Epidemiol* 2001;54(3):316-22.
22. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons [see comments]. *Jama* 1995;274(7):539-44.
23. Lan TY, Lan TH, Wen CP, Lin YH, Chuang YL. Nighttime sleep, Chinese afternoon nap, and mortality in the elderly. *Sleep* 2007;30(9):1105-10.
24. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. *J Intern Med* 2002;251(3):207-16.
25. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gauden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Archives of Internal Medicine* 2001;161(15):1849-56.
26. Blazer DG, Hybels CF, Pieper CF. The association of depression and mortality in elderly persons: a case for multiple, independent pathways. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2001;56(8):M505-9.
27. Dubielzig RR, Hawkins KL, Miller PE. Myofibroblastic sarcoma originating at the site of rabies vaccination in a cat. *J Vet Diagn Invest* 1993;5(4):637-8.
28. Hendrick MJ, Dunagan CA. Focal necrotizing granulomatous panniculitis associated with subcutaneous injection of rabies vaccine in cats and dogs: 10 cases (1988-1989). *J Am Vet Med Assoc* 1991;198(2):304-5.
29. Peters R, Pinto E, Beckett N, Swift C, Potter J, McCormack T, et al. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing* 2010;39(4):439-45.
30. Janzing JG, Bouwens JM, Teunisse RJ, Van't Hof MA, Zitman FG. The relationship between depression and mortality in elderly subjects with less severe dementia. *Psychological Medicine* 1999;29(4):979-83.
31. Gruffydd-Jones TJ, Sparkes AH. Vaccination and fibrosarcomas in cats. *Vet Rec* 1994;134(12):310.
32. de Souto Barreto P, Ferrandez AM, Saliba-Serre B. Are Older Adults Who Volunteer to Participate in an Exercise Study Fitter and Healthier than Non-Volunteers? The participation bias of the study population. *J Phys Act Health* 2012.
33. Nummela O, Sulander T, Helakorpi S, Haapola I, Uutela A, Heinonen H, et al. Register-based data indicated nonparticipation bias in a health study among aging people. *J Clin Epidemiol* 2011;64(12):1418-25.
34. Boyd CM, Darer J, Boulton C, Fried LP, Boulton L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA* 2005;294(6):716-24.

## Golomb 2012 – Elderly Nonrepresentative

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
35. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. *Arch Intern Med* 2010;170(18):1648-54.
36. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. *Isr Med Assoc J* 2007;9(6):430-4.

Golomb 2012 – Elderly Nonrepresentative

Table 1. Self-Rated “Relative Activity”\* Predicts-Relates to Health-Predictors in Age > 50 Those Over (Age > 50)

Variable	Correlation Coefficient	P-value	Regression Coefficient, age adjusted†	P-value	Age Relation, sign and P-value
Times/wk exercise at least 20minutes	0.42	<0.0001	1.2 (0.092)	<0.001	(-) 0.024
CES-D (0-52)	-0.21	<0.0001	-1.3 (0.23)	<0.001	NS
Depressed (0-10)	-0.13	0.0083	-0.21 (0.086)	0.017	NS
Energy (0-10)	0.21	<0.0001	0.34 (0.064)	<0.001	(+) 0.031
Sleep problems (0-10)	-0.084	0.028	-0.21 (.095)	0.024	NS
Sleep quality (0-30)	0.078	0.036	0.037 (0.011)	0.001	(+) 0.081
Tired (0-10)	-0.29	<0.0001	-0.72 (0.13)	<0.001	(+) 0.001
Muscle weakness	-0.14	<0.0001	-0.29 (0.070)	<0.001	(+) 0.005
Fatigue w Exertion (0-10)	-0.26	<0.0001	-0.61 (0.12)	<0.001	(+) 0.002
Health (0-10)	0.20	<0.0001	0.31 (0.061)	<0.001	(+) 0.071
Satisfaction with health (0-100)	0.30	<0.0001	5.6 (0.69)	<0.001	NS
Glucose (mg/dL) ‡	-0.073	0.049	-0.73 (0.31)	0.019	(+) 0.014
HDL (mg/dL)	0.10	0.0063	1.2 (0.53)	0.028	(+) 0.001
Triglycerides (mg/dL)	-0.17	<0.0001	-10 (2.3)	<0.001	NS
Body mass index	-0.26	<0.0001	-0.97 (0.15)	<0.001	(-) 0.002
Waist (cm)	-0.23	<0.0001	-3.9 (0.63)	<0.001	NS
Platelets	-0.073	0.051	-2.7 (1.7)	0.11	(-) 0.043
White blood cell count	-0.08	0.027	-0.125 (0.050)	+0.012	(+) 0.058

Formatted

CES-D – Center for Epidemiological Studies -Depression scale, HDL – high density lipoprotein cholesterol, NS – non-significant.

\* Level of activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active. Relative Activity”: self rated physical activity relative to others ones age

† Regression examines relative activity level relation to health predictor, among those age > 50, with age as an adjusted covariate in the regressions.

(The column to the far right gives the sign of the coefficient for the age variable, and its significance.)

‡ Note: patients with diabetes or measured glucose over 142 were excluded. This finding is thus despite range restriction.

Note that in these study subjects/participants, there is a “paradoxically” favorable age association for some variables that generally worsen with rising age, including energy, sleep quality, health, and HDL-cholesterol.

## Golomb 2012 – Elderly Nonrepresentative

Table 2. “Relative Activity” Ratings\*, by Age

	Clinical Trial Sample		Observational Sample	
Age Decade	N	Relative Activity* Mean (SD)	N	Relative Activity* Mean (SD)
30s	80	3.35 (1.02)	34	3.26 (1.24)
40s	180	3.30 (1.20)	565	3.27 (1.23)
50s	308	3.49 (1.20)	650	3.68 (1.15)
60s	261	3.92 (1.07)	569	3.94 (1.05)
70s	151	3.89 (1.01)	512	3.97 (1.04)
80s	20	4.10 (1.07)	24	4.17 (1.31)
Significance of Change by Age Decade		$P < 0.001$		$P < 0.001$

N—Number; SD—Standard deviation

\* Level of physical activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.

Golomb 2012 – Elderly Nonrepresentative

**Table 3. Older Participant Age Associated with Greater Self-reported “Relative Activity”<sup>\*,†</sup>, Ordinal Logit Analyses**

	Clinical Trial Sample				Observational Sample			
	Coefficient for Age Decade	Standard Error	p-value	95% Confidence Interval	Coefficient for Age Decade	Standard Error	p-value	95% Confidence Interval
<b>Unadjusted</b>	0.29	0.044	<0.001	0.21, 0.38	0.37	0.034	<0.001	0.31, 0.44
<b>Multivariable adjusted<sup>‡</sup></b>	0.35	0.052	<0.001	0.25, 0.45	0.37	0.035	<0.001	0.30, 0.44

\*Relative Activity level (self-rated physical activity relative to others your age) was theas\* Level of activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active. †outcome, adjusted for age, gender, ethnicity, and education level.

‡Ordinal logit.

Golomb 2012 – Elderly Nonrepresentative

Table 32. “Relative-Activity” Ratings-Ratings\*, by Age

	Clinical Trial Sample		Observational Sample	
Age Decade	N	Relative Activity* Mean (SD)	N	Relative Activity* Mean (SD)
30s	80	3.35 (1.02)	34	3.26 (1.24)
40s	180	3.30 (1.20)	565	3.27 (1.23)
50s	308	3.49 (1.20)	650	3.68 (1.15)
60s	261	3.92 (1.07)	569	3.94 (1.05)
70s	151	3.89 (1.01)	512	3.97 (1.04)
80s	20	4.10 (1.07)	24	4.17 (1.31)
Significance of Change by Age Decade		P < 0.001		P < 0.001

N – Number; SD – Standard deviation

\* Level of physical activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.

Golomb 2012 – Elderly Nonrepresentative

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49



Golomb 2012 – Elderly Nonrepresentative

**Table 3. Older Participant Age Associated with Greater Self-reported “Relative-Activity”\*, Ordinal Logit Analyses**

	<u>Clinical Trial Sample</u>				<u>Observational Sample</u>			
	<u>Coefficient for Age Decade</u>	<u>Standard Error</u>	<u>P-value</u>	<u>95% CI</u>	<u>Coefficient for Age Decade</u>	<u>Standard Error</u>	<u>P-value</u>	<u>95% CI</u>
<b><u>Unadjusted</u></b>	<u>0.29</u>	<u>0.044</u>	<u>&lt;0.001</u>	<u>0.21, 0.38</u>	<u>0.37</u>	<u>0.034</u>	<u>&lt;0.001</u>	<u>0.31, 0.44</u>
<b><u>Multivariable adjusted†</u></b>	<u>0.35</u>	<u>0.052</u>	<u>&lt;0.001</u>	<u>0.25, 0.45</u>	<u>0.37</u>	<u>0.035</u>	<u>&lt;0.001</u>	<u>0.30, 0.44</u>

CI – Confidence interval\* Level of activity “compared to other persons your age” measured on a 5-point Likert scale: 1=much less active, 2=somewhat less active, 3=about as active, 4=somewhat more active, 5=much more active.†Ordinal logit adjusted for age, gender, ethnicity, and education level.

Golomb 2012 – Elderly Nonrepresentative

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49